Apoptosis and caspases in neurodegenerative diseases

New England Journal of Medicine

Volumn 348, Issue 14, 2003, Pages 1365-1375

  Friedlander, Robert M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 11; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MINOCYCLINE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CHRONIC DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; HUNTINGTON CHOREA; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SURVIVAL; SYMPTOMATOLOGY; TRANSCRIPTION REGULATION;

ACUTE DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CASPASES; CYTOCHROME C GROUP; HUMANS; HUNTINGTON DISEASE; MICE; MINOCYCLINE; NEURODEGENERATIVE DISEASES;

EID: 0037417220     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra022366     Document Type: Review

References (98)

1. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000;407:802-9.
2. Rossi F, Cattaneo E. Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci 2002;3:401-9.
3. Kuhn HG, Palmer TD, Fuchs E. Adult neurogenesis: a compensatory mechanism for neuronal damage. Eur Arch Psychiatry Clin Neurosci 2001;251:152-8.
4. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-7.
5. Liu J, Solway K, Messing RO, Sharp FR. Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci 1998;18:7768-78.
6. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
7. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance ofapoptosis. Int Rev Cytol 1980;68:251-306.
8. Kanduc D, Mittelman A, Serpico, R, et al. Cell death: apoptosis versus necrosis. Int J Oncol 2002;21:165-70.
9. Martin LJ. Neuronal cell death in nervous system development, disease, and injury. Int J Mol Med 2001;7:455-78.
10. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993;24:2002-9.
11. Emery E, Aldana P, Bunge MB, et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg 1998;89:911-20.
12. Kerr JF, Wyllie AH, Currie AR, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
13. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340:1970-80. [Erratum, N Engl J Med 1999; 341:1407.]
14. Charriaut-Marlangue C, Margaill I, Represa A, Popovici T, Plotkine M, Ben-Ari Y. Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab 1996;16:186-94.
15. Li Y, Chopp M, Jiang N, Zaloga C. In situ detection of DNA fragmentation after focal cerebral ischemia in mice. Brain Res Mol Brain Res 1995;28:164-8.
16. MacManus JP, Buchan AM, Hill IE, Rasquinha I, Preston E. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neurosci Lett 1993; 164:89-92.
17. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-6. [Erratum, Nat Med 1997;3:240.]
18. Li M, Ona VO, Chen M, et al. Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury. Neuroscience 2000;99:333-42.
19. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997;17:5395-406.
20. Rink A, Fung KM, Trojanowski JQ Lee VM, Neugebauer E, McIntosh TK. Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol 1995;147:1575-83.
21. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 1995;133:265-72.
22. Troost D, Aten J, Morsink F, deJong JM. Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons: Bcl-2 expression is increased in unaffected post-central gyrus. Neuropathol Appl Neurobiol 1995;21: 498-504.
23. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995;133:225-30.
24. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284:555-6.
25. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89: 175-84.
26. Horvitz HR. Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res 1999;59: Suppl:1701s-1706s.
27. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993;75:641-52.
28. Yuan JY, Horvitz HR. The Caenorditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 1990;138:33-41.
29. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction ofapoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993;75:653-60.
30. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91: 479-89.
31. Hengartner MO, Horvitz HR, C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994;76:665-76.
32. Conradt B, Horvitz HR, The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 1998;93:519-29.
33. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
34. Shi Y. Mechanisms ofcaspase activation and inhibition during apoptosis. Mol Cell 2002;9:459-70.
35. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
36. Fink KB, Andrews LJ, Butler WE, et al. Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade. Neuroscience 1999; 94:1213-8.
37. Friedlander RM, Yuan J. ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ 1998;5:823-31.
38. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288:335-9.
39. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999;399:263-7.
40. Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2000;97:13901-6.
41. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M. Inhibition of caspase-1-like activity by Ac-TyrVal-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 2000;20:4398-404.
42. Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002;22: 6537-48.
43. Vukosavic S, Stefanis L, Jackson-Lewis V, et al. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000;20:9119-25.
44. Friedlander RM, Gagliardini V, Hara H, et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med 1997;185:933-40.
45. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-6.
46. Bouchier-Hayes L, Martin SJ. CARD games in apoptosis and immunity. EMBO Rep 2002;3:616-21.
47. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96-9.
48. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391: 43-50. [Erratum, Nature 1998;393:396.]
49. Liu X, Li P, Widlak P, et al. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci U S A 1998;95:8461-6.
50. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 1999;96:13496-500.
51. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998;95:15769-74.
52. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
53. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15: 2922-33.
54. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
55. Deveraux QL, Schendel SL, Reed JC. Antiapoptotic proteins: the bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin 2001;19:57-74.
56. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway ofapoptosis. Cell 1998;94:491-501.
57. Xu D, Bureau Y, McIntyre DC, et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci 1999;19:5026-33.
58. Troy CM, Salvesen GS. Caspases on the brain. J Neurosci Res 2002;69:145-50.
59. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci 1997; 17:7415-24.
60. Springer JE, Azbill RD, Knapp PE. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med 1999; 5:943-6.
61. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J. Inhibition of ICE slows ALS in mice. Nature 1997;388:31. [Erratum, Nature 1998;392:560.]
62. Gervais FG, Xu D, Robertson GS, et al. Involvement ofcaspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999;97:395-406.
63. Loddick SA, MacKenzie A, Rothwell NJ. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport 1996;7:1465-8. [Erratum, Neuroreport 1999;10(9):inside back cover.]
64. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interlenkin 1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A 1997;94:2007-12.
65. Kang SJ, Wang S, Hara H, et al. Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol 2000;149:613-22.
66. Benchoua A, Guegan C, Couriaud C, et al. Specific caspase pathways are activated in the two stages of cerebral infarction. J Neurosci 2001;21:7127-34.
67. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression ofamyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
68. Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994;13:1017-30.
69. Plesnila N, Zinkel S, Le DA, et al. BID mediates neuronal cell death after oxygenglucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci U S A 2001;98: 15318-23.
70. Schielke GP, Yang GY, Shivers BD, Betz AL. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 1998;18: 180-5.
71. Fink K, Zhu J, Namura S, et al. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab 1998;18:1071-6.
72. Garden GA, Budd SL, Tsai E, et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002;22:4015-24.
73. Klivenyi P, Andreassen O, Ferrante RJ, Schleicher JR Jr, Friedlander RM, Beal MF. Transgenic mice expressing a dominant negative mutant interleukin-1 beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 1999;10:635-8.
74. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344: 1688-700.
75. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362: 59-62. [Erratum, Nature 1993;364:362.]
76. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-5. [Erratum, Science 1995;269:149.]
77. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-50.
78. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58:459-71.
79. Guegan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001;21:6569-76.
80. Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277:559-62.
81. Harper PS. Huntington's disease. London: W.B. Saunders, 1991.
82. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
83. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
84. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998;20:198-202.
85. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-97.
86. Li SH, Lam S, Cheng AL, Li XJ. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum Mol Genet 2000;9:2859-67.
87. Kiechle T, Dedeoglu A, Kubilus J, et al. Cytochrome c and caspase-9 expression in Huntington's disease. Neuromolecular Med 2002;1:183-95.
88. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999;22:623-33.
89. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-8.
90. Rigamonti D, Bauer JH, De-Fraja C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000;20:3705-13
91. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 2001;276:14545-8.
92. Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996;13:442-9.
93. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage ofgene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998;273: 9158-67.
94. Nucifora FC Jr, Sasald M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001;291:2423-8.
95. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 1998;95:6480-5.
96. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methylD-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-33.
97. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393-401.
98. Shuman SL, Bresnahan JC, Beattie MS. Apoptosis of microglia and oligodendrocytes after spinal cord contusion in rats. J Neurosci Res 1997;50:798-808.